Development of specific inhibitors of TLR7-sensing 2′-O-methylated RNAs may facilitate future therapeutic strategies to manage complex immunometabolic disorders such as obesity and atherosclerosis. Here, TLR7 is linked to obesity due to melanocortin 4 receptor deficiency.